ARMONAIR DIGIHALER Drug Patent Profile

When do Armonair Digihaler patents expire, and when can generic versions of Armonair Digihaler launch?

Armonair Digihaler is a drug marketed by Teva Pharm and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and eighty-eight patent family members in thirty-two countries.

The generic ingredient in ARMONAIR DIGIHALER is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Armonair Digihaler

A generic version of ARMONAIR DIGIHALER was approved as fluticasone propionate by ENCUBE on May 14^th, 2004.

Summary for ARMONAIR DIGIHALER

International Patents:	188
US Patents:	5
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	86
Patent Applications:	571
Drug Prices:	Drug price information for ARMONAIR DIGIHALER
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARMONAIR DIGIHALER
What excipients (inactive ingredients) are in ARMONAIR DIGIHALER?	ARMONAIR DIGIHALER excipients list
DailyMed Link:	ARMONAIR DIGIHALER at DailyMed

See drug prices for ARMONAIR DIGIHALER

US Patents and Regulatory Information for ARMONAIR DIGIHALER

ARMONAIR DIGIHALER is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-008	Apr 8, 2022		DISCN	Yes	No	11,344,685*PED				Y
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-006	Feb 20, 2020		DISCN	Yes	No	11,344,685*PED				Y
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-004	Feb 20, 2020		DISCN	Yes	No	11,173,259*PED				Y
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-008	Apr 8, 2022		DISCN	Yes	No	10,918,816*PED				Y

Expired US Patents for ARMONAIR DIGIHALER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-006	Feb 20, 2020	8,006,690
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-004	Feb 20, 2020	6,748,947
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-005	Feb 20, 2020	6,701,917
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-004	Feb 20, 2020	6,701,917

International Patents for ARMONAIR DIGIHALER

See the table below for patents covering ARMONAIR DIGIHALER around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	247401
European Patent Office	3057637	MODULE DE SURVEILLANCE DE LA CONFORMITÉ POUR UN INHALATEUR ACTIONNÉ PAR LA RESPIRATION (COMPLIANCE MONITORING MODULE FOR A BREATH-ACTUATED INHALER)
Japan	4700005
South Africa	201307996

Supplementary Protection Certificates for ARMONAIR DIGIHALER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1305329	08C0014	France		PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
1519731	92269	Luxembourg		PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE

ARMONAIR DIGIHALER Market Analysis and Financial Projection

Last updated: February 14, 2026

Market Dynamics and Financial Trajectory for ARMONAIR DIGIHALER

Current Market Position

ArmonAir Digihaler is a prescription inhaler developed by Teva Pharmaceuticals, approved primarily for asthma and chronic obstructive pulmonary disease (COPD). It combines enhanced digital features with traditional inhaler design, featuring built-in sensors that monitor medication usage and provide data to patients and providers.

Since its introduction in 2020, ARMONAIR DIGIHALER has captured a niche segment within the broader respiratory therapy market, which was valued at approximately $27 billion globally in 2022. Teva's integration of digital health tools aligns with industry trends toward connected devices, expected to expand at a compound annual growth rate (CAGR) of 28%, driven by increasing adoption of digital health monitoring and telemedicine.

Market Drivers

1. Digital Health Integration
   ARMONAIR DIGIHALER differentiates through its digital capabilities, which enable adherence tracking and remote monitoring. This aligns with Physician and patient preferences for more personalized management, encouraging usage and improving health outcomes.

2. Increasing Prevalence of Respiratory Diseases
   The global burden of asthma affects over 300 million people, with COPD impacting more than 200 million. Rising prevalence fuels demand for effective delivery devices, including digitized inhalers.

3. Regulatory Support for Digital Devices
   Agencies like the FDA approve digital health applications, boosting market confidence. The recently approved FDA guidance encourages integration of digital features in inhalation products, paving the way for broader acceptance.

4. Market Penetration and Reimbursement
   Reimbursement codes for digital inhalers are evolving, with Medicare and private insurers gradually covering digital adherence tools. This facilitates patient access and provider uptake.

Competitive Landscape

ARMONAIR places itself among devices like the Propeller Smart Inhaler (Teva), SensorMedica's Smart Inhaler, and GSK’s Ellipta series with digital autorotation features. Key differentiators include:

• Digital monitoring with cloud connectivity.
• Data sharing capabilities for clinicians.
• Device integration with mobile applications for patient engagement.

Financial Trajectory and Revenue Forecast

Teva does not disclose specific revenue figures solely for ARMONAIR DIGIHALER. However, considering the respiratory inhaler market's growth and digital health trends, projections suggest:

Year	Estimated Market Share	Potential Revenue (USD millions)	Underlying Assumptions
2023	2% of global inhaler sales	$50 - $75	Based on total inhaler sales of $2.5 billion, CAGR of 4%
2025	4%	$100 - $150	Increased adoption, expanded reimbursement coverage
2030	8-10%	$250 - $400	Digital adherence tools become standard, market maturation

The growth hinges on:

• Expansion into the U.S. and European markets.
• Increased physician adoption driven by digital health benefits.
• Regulatory approvals for new indications or enhanced features.

Barriers to Growth

1. Pricing and Reimbursement Challenges
   Higher costs of digital inhalers may limit adoption without adequate insurance coverage.

2. Competitive Innovation
   Major pharmaceutical companies are investing in digital inhalers, potentially increasing market competition.

3. Regulatory Uncertainties
   Future guidance on digital health products could impact marketability and reimbursement pathways.

4. Patient Engagement
   Dependence on patient acceptance of digital tools impacts actual adherence improvements.

---

Key Takeaways

• ARMONAIR DIGIHALER is positioned within a growing digital health segment of the respiratory device market.
• Market expansion relies on increasing disease prevalence, digital health adoption, and evolving reimbursement policies.
• Estimated revenues for Teva could reach USD 250-400 million by 2030 with sustained market penetration.
• Competition and regulatory factors significantly influence future growth trajectories.
• Adoption depends on physician and patient receptivity to digital inhaler benefits.

---

FAQs

1. What is the market size for digital inhalers globally?
The global digital inhaler market was valued around $370 million in 2022 and is expected to grow at approximately 28% CAGR, reaching over $1 billion by 2028.

2. How does ARMONAIR DIGIHALER compare to traditional inhalers?
It adds digital sensors that enable adherence tracking, remote monitoring, and data sharing, which traditional inhalers lack.

3. What are the main barriers to expanding ARMANAIR DIGIHALER's market share?
High device costs, reimbursement hurdles, competition from other digital inhalers, and patient acceptance of digital monitoring.

4. Which regions offer the greatest growth opportunities?
The U.S. and Europe offer the largest markets for digital respiratory devices due to high disease prevalence and favorable regulatory environments.

5. Are there ongoing clinical trials or regulatory updates relevant to ARMONAIR?
Current data indicates ongoing post-market studies on adherence and device efficacy, with regulatory focus on digital health certification.

---

References

1. MarketWatch. Global Digital Inhaler Market Size, Trends, and Forecasts, 2022-2028.
2. FDA Guidance for Digital Health Devices, 2022.
3. Global Burden of Disease Study 2019.
4. Teva Pharmaceuticals Annual Reports, 2022.
5. IQVIA. Global Respiratory Devices Market Overview, 2022.